Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice.
about
Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cellsInvestigational inhibitors of PTP4A3 phosphatase as antineoplastic agents.PRL-3 suppresses c-Fos and integrin α2 expression in ovarian cancer cells.Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy.PRL-3 activates mTORC1 in Cancer Progression.Linked-in: design and efficacy of antibody drug conjugates in oncologyRibonuclease binase inhibits primary tumor growth and metastases via apoptosis induction in tumor cells.Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia.PRL3-zumab, a first-in-class humanized antibody for cancer therapy.Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survivalExpression of phosphatase of regenerating liver-3 is associated with prognosis of Wilms' tumor.Monoclonal antibodies as therapeutics in human malignancies.Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies.Molecular targets and pathways involved in liver metastasis of colorectal cancer.Intracellular antigens as targets for antibody based immunotherapy of malignant diseases.Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody.Therapeutic Antibodies against Intracellular Tumor AntigensCharacterization and Expression of Senescence Marker in Prolonged Passages of Rat Bone Marrow-Derived Mesenchymal Stem Cells.Suppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3.Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases.New Approaches to Difficult Drug Targets: The Phosphatase Story
P2860
Q27852452-DDCB0DAC-98EF-421E-8B85-88BCE321A59CQ30457615-6B1B9452-7FB0-4758-BE56-484817EB6D94Q34590459-DA89D29E-DE62-4E3B-9AD9-4E8246B3C3F0Q35626579-7C00F731-0EBC-498F-A880-58254744D997Q36310169-DF90EE6F-2BF6-4768-A240-50FE0882AF27Q37029370-151594F2-DF05-402C-9D44-92E8A651ABA9Q37079775-CA43AB40-928F-434F-A76B-E31D91AFC6ABQ37236903-DDC99FFC-A2EC-4A60-8811-4EED2004AA02Q37277211-F1A428B8-1288-4294-B7D0-963B129FA2DDQ37299271-EBB9DCB0-3E90-4F7B-B9EE-5A86C16D579FQ37587207-366C5412-3603-41AE-9754-807E125CBDCAQ38206275-6C48B7D3-FC00-45E7-94B4-C85B81B569FDQ38285175-9E09F0B8-7916-4A1D-B3F6-B3501C3A55C7Q38535666-091024E9-79EE-4C21-9CDF-48A01172DDB1Q38644355-649BD739-41CE-402A-837A-D8373FF39B12Q39085019-B7F61B2F-A303-4002-9C08-8479000AFA0FQ41462883-3A6D7037-69F4-4863-A99F-878F04280DA1Q41693126-5B03A519-10C3-4CD6-AC59-B143E3F5652CQ43522873-2636D67D-01EA-402B-A66A-1EFA7054AA6AQ47123783-964EB2D6-AD24-40BE-B6E1-97312BE68E10Q48103763-EF4A8351-BB48-405A-98FC-7B13774B9E75Q56513340-01BA185E-0E35-482F-B408-B041E4FFBEB0
P2860
Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Engineering the first chimeric ...... in for cancer therapy in mice.
@ast
Engineering the first chimeric ...... in for cancer therapy in mice.
@en
type
label
Engineering the first chimeric ...... in for cancer therapy in mice.
@ast
Engineering the first chimeric ...... in for cancer therapy in mice.
@en
prefLabel
Engineering the first chimeric ...... in for cancer therapy in mice.
@ast
Engineering the first chimeric ...... in for cancer therapy in mice.
@en
P2093
P2860
P356
P1433
P1476
Engineering the first chimeric ...... in for cancer therapy in mice.
@en
P2093
Abdul Qader O Al-Aidaroos
Cheng Peow Bobby Tan
Cheng William Hong
Jianbiao Zhou
Jing Ping Tang
Jung Eun Park
Leyon Varghese
P2860
P304
P356
10.18632/ONCOTARGET.442
P407
P577
2012-02-01T00:00:00Z